SCHEMBL4891097

SCHEMBL4891097

NS(=O)(=O)c1ccc2c(c1)C1(CCN(CCC(F)(F)F)CC1)CN2C(=O)c1c(F)cccc1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 3/20 0.40
CA1 P00915 4/20 0.37
CA2 P00918 4/20 0.37
CA12 O43570 3/20 0.37
CA9 Q16790 3/20 0.37
CA7 P43166 2/20 0.37
JAK2 O60674 2/20 0.36
JAK1 P23458 2/20 0.36
TYK2 P29597 2/20 0.36
JAK3 P52333 2/20 0.36
PLK4 O00444 1/20 0.35
STK25 O00506 1/20 0.35
RIOK3 O14730 1/20 0.35
AURKA O14965 1/20 0.35
GAK O14976 1/20 0.35
DCLK1 O15075 1/20 0.35
PDPK1 O15530 1/20 0.35
DAPK3 O43293 1/20 0.35
NUAK1 O60285 1/20 0.35
ROCK2 O75116 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4888659 0.91 DRD2 (0.36) RORCPSEN1PSEN2APH1BNCSTN
SCHEMBL4881930 0.85 RORC (0.45) RORC
SCHEMBL4893344 0.85 OPRM1 (0.41) MAPK1EPHX2
SCHEMBL4884630 0.85 NOTUM (0.47) RORCEPHX2PSEN1PSEN2APH1B
SCHEMBL4893251 0.84 P2RY1 (0.36) RORCEPHX2
SCHEMBL4884659 0.83 EPHX2 (0.40) MAPK1EPHX2
SCHEMBL4886630 0.83 SLC18A3 (0.35) RORCEPHX2
Trifluoroacetic Acid SCHEMBL4761896 0.81 OPRM1 (0.36) EPHX2
Trifluoroacetic Acid SCHEMBL4761761 0.80 S1PR1 (0.34) EPHX2
SCHEMBL4893188 0.77 NOTUM (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080200491-A1 1,2-Dihydro-Spiro[3H-Indole-3,4'-Piperidine] Compounds, as Modulators of the Mas Receptor Novel ARENA PHARMACEUTICALS, INC. 2008-08-21 US claimed
US-20080200491-A1 1,2-Dihydro-Spiro[3H-Indole-3,4'-Piperidine] Compounds, as Modulators of the Mas Receptor Novel ARENA PHARMACEUTICALS, INC. 2008-08-21 US disclosed
US-20080200491-A1 1,2-Dihydro-Spiro[3H-Indole-3,4'-Piperidine] Compounds, as Modulators of the Mas Receptor Novel ARENA PHARMACEUTICALS, INC. 2008-08-21 US disclosed
US-20080200491-A1 1,2-Dihydro-Spiro[3H-Indole-3,4'-Piperidine] Compounds, as Modulators of the Mas Receptor Novel ARENA PHARMACEUTICALS, INC. 2008-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200491-A1 1,2-Dihydro-Spiro[3H-Indole-3,4'-Piperidine] Compounds, as Modulators of the Mas Receptor Novel AGTR1, AGTR2, AVPR2 RORC 1081/4885CA1 1735/4885CA2 939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.